期刊文献+

针对T315I突变的Bcr-Abl酪氨酸激酶抑制剂研究进展 被引量:6

Advances in Research on Bcr-Abl Tyrosine Kinase Inhibitors against T315I Mutation1,2221
原文传递
导出
摘要 BCR-ABL是一种由bcr基因和c-abl原癌基因融合产生的致癌基因。该基因表达的Bcr–Abl癌蛋白是慢性粒细胞白血病的病理学基础。因此研发选择性的Bcr–Abl酪氨酸激酶抑制剂成为治疗慢性粒细胞白血病的一种有效策略。目前已有数个Bcr–Abl酪氨酸激酶抑制剂获准上市。然而,Abl激酶结构域的突变或其他原因导致肿瘤耐药性的出现,其中T315I突变是最重要的突变之一,引发的耐药性更是难以克服。重点介绍了针对T315I突变的Bcr–Abl酪氨酸激酶抑制剂的研究进展。 BCR-ABL is an oncogene that arises from the fusion of the bcr gene and the c-abl proto-oncogene. The Bcr-Abl oncoprotein is believed to be the primary cause of chronic myelogenous leukemia (CML). Thus, the development of selective Bcr-Abl kinase inhibitors is an attractive strategy to treat CML. Several Bcr-Abl tyrosine kinase inhibitors (Bcr-Abl TKIs) have been approved recently. However, multiple drug resistance of tumor cells against the existing Bcr-Abl TKIs has emerged due to the mutations in the Abl kinase domain or other reasons. Among them the T315I mutation is the most difficult one to be treated. The recent progress in research on Bcr-Abl TKIs against T3151 mutation has been reviewed in this paper.
出处 《药学进展》 CAS 2014年第5期333-339,共7页 Progress in Pharmaceutical Sciences
关键词 酪氨酸激酶 慢性粒细胞白血病 Bcr-Abl激酶抑制剂 耐药性 天冬氨酸-苯丙氨酸-甘氨酸基序 tyrosine kinase chronic myelogenous leukemia Bcr-Abl kinase inhibitor drug resistance DFG motif
  • 相关文献

参考文献27

  • 1Rowley J D. Letter: A new consistent chromosomal abnormality in chronic myelogenous leukaemia identified by quinacrine fluorescence and Giemsa staining [J]. Nature, 1973, 243 (5405): 290-293.
  • 2Davis R L, Konopka J B, Witte O N. Activation of the e-abl oncogene by viral transduction or chromosomal translocation generates altered c-abl proteins with similar in vitro kinase properties [J]. Mol Cell Biol, 1985, 5 ( 1 ): 204-213.
  • 3Daley G Q, Van Etten R A, Baltimore D. Induction of chronic myelogenous leukemia in mice by the P210bcr/abl gene of the Philadelphia chromosome [J]. Science, 1990, 247 (4944): 824-830.
  • 4Shawver L K, Slamon D, Ullrich A. Smart drugs: tyrosine kinase inhibitors in cancer therapy [J]. Cancer cell, 2002, 1 (2): 117-123.
  • 5Zuccotto F, Ardini E, Casale E, et al. Through the "gatekeeper door": exploiting the active kinase contbrmation [J]. J Med Chem, 2010, 53 (7): 2681-2694.
  • 6Olivieri A, Manzione L. Dasatinib: a new step in molecular target therapy [J]. Ann Oncol, 2007, 18 (6): 42-46.
  • 7O'hare T, Zabriskie M S, Eiring A M, et al. Pushing the limits of targeted therapy inchronie myeloid leukaemia [J]. Nat Rev Cancer, 2012, 12(8): 513-526.
  • 8Zhao F, Mancuso A, Bui T V, et al. Imatinib-resistance associated with BCR-ABL upregulation is dependent on HIF-la-induced metabolic reprogramming [J]. Oncogene, 2010, 29 (20): 2962-2972.
  • 9Le Coutre P, Kreuzer K A, Pursehe S, et al. Pharmacokinetics and cellular uptake of imatinib and its main metabolite CGP74588 [J].Cancer Chemother Pharmacol, 2004, 53 (4): 313-323.
  • 10Meyn M A 3rd, Wilson M B, Abdi F A, et al. Src family kinases phosphorylate the Bcr-Abl SH3-SH2 region and modulate Bcr-Abl transforming activity [J]. JBiol Chem, 2006, 281 (41): 30907-30916.

同被引文献50

  • 1Vardiman JW,Melo JV,Baccarani M,et al.Chronic myelogenous leukaemia[M].France:IARC Press Lyon,2008:32-37.
  • 2Deininger MWN,Goldman JM,Melo JV.The molecular biology of chronic myeloid leukemia[J].Blood,2000,96(10):3 343-3356.
  • 3Davis RL,Konopka JB,Witte ON.Activation of the c-ABL oncogene by viral transduction or chromosomal translocation generates altered c-ABL proteins with similar in vitro kinase properties[J].Mol Cell Biol,1985,5(1):204-213.
  • 4Christopher J Lord,Alan Ashworth.Biology-driven cancer drug development:back to the future[J].BMC Biology,2010,8(38):1 741-1 753.
  • 5Brien SG,Guilhot F,Larson RA,et al.Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronicphase chronic myeloid leukemia[J].N Engl J Med,2003,34(8):994-1 004.
  • 6Muvarak N,Nagaria P,Rassool FV.Genomic Instability in chronicmyeloid leukemia targets for therapy[J].Curr Hematol Malig Rep,2012,23(7):94-102.
  • 7NCCN Clinical Practice Guidelines in Oncology[EB/OL].[2012-11 -23].www.nccn.org/professionals/physiciangls/guidelines.
  • 8Druker BJ,Guilhot F,O-Brien SG,et al.Five years follow-up of patients receiving imatinib for chronic myeloid leukemia[J].N Engl J Med,2006,35(5):2 408-2 417.
  • 9Testoni N,Marzocchi G,Luatti S,et al.Chronic myeloid leukemia:aprospective comparison of interphase fluorescence in situ hybridization and chromosome banding analysis for the definition of complete cytogenetic response[J].Blood,2009,114(24):4 939-4 943.
  • 10Dewald G,Schad C,Christensen E,et al.The application of fluorescent in situ hybridization to detect MBCR/ABL fusion in variant Ph chromosomes in CML and ALL[J].Cancer Genet Cytogenet,1993,71(1):7-14.

引证文献6

二级引证文献29

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部